Harrow Inc (HROW) Actualités

Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients

Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced the launch of its “Harrow Cares” program through...

Harrow Appoints Amir H. Shojaei as Chief Scientific Officer

Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that Amir H. Shojaei, PharmD, PhD, has joined...

Harrow’s ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.

Jury in Trademark Infringement Case Finds in Favor of ImprimisRx Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company...

Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery

MELT-300 Demonstrates Statistically Superior Compared to Both Sublingual Midazolam (P=0.009) and Placebo (P<0.001) for Providing Successful...

Harrow Announces Participation in Upcoming Investor Conferences

Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following...

Harrow Announces Third Quarter 2024 Financial Results

Third Quarter 2024 and Recent Selected Highlights: Revenues increased 44% from $34.3 million in the prior-year quarter to $49.3 million GAAP net...

Harrow Launches Access and Affordability Program with Price Reductions for Branded Products

New Partnership with GoodRx to Lower Costs for Uninsured and Underinsured Patients Harrow (Nasdaq: HROW), a leading North American eyecare...

Harrow Announces Market Access Wins for VEVYE®

Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced its first major market access wins in the 2025...

Harrow Partners with Asembia to Enhance Provider and Patient Experience Through Nationwide Digital Services and Hub Support for Harrow’s Branded Eyecare Products

Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced the nationwide launch of a new digital patient...

Harrow To Report Third Quarter 2024 Financial Results After Market Close on November 13, 2024

Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on November 14, 2024 Harrow (Nasdaq: HROW), a leading North...

Melt Pharmaceuticals Announces Dosing of Last Patient in Pivotal Phase 3 Study of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery

Topline Readout Expected in Q4 2024 FDA Agrees to a MELT-300 Phase 3 Special Protocol Assessment Melt Pharmaceuticals, Inc. (“Melt”), a...

Harrow Relaunches TRIESENCE®

Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced the relaunch of TRIESENCE® (triamcinolone acetonide...

Harrow Announces Nashville Expansion

Leading U.S. ophthalmic pharmaceutical company to create nearly 150 new jobs in Nashville Tennessee Governor Bill Lee, Department of Economic...

Harrow to Present at Three Investor Conferences in September in New York

Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]